Mallinckrodt stock rises 23% on sales of its most controversial product
August 07, 2018 at 10:14 AM EDT
The product has been criticized for its high price, or nearly $40,000 a year, and its effectiveness has been questioned.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|